Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Investing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Investing cash flow turns negative

Q3 FY2026 investing cash flow was -$3.8M, compared with $25M a year earlier. Trailing-twelve-month investing cash flow was -$492.54M.

Context

  • Investing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near -$3.8M or moves back toward the trailing-twelve-month quarterly average of -$123.13M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$3.8M-98.7% QoQ
Last fiscal yearDec 2025
-$143.48M-59.4% YoY
LTMSep 2026
-$492.54M+639.4% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-115.2%——
1 year-59.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(143.48M) USD
Year-over-year change
+59.4%

Investing Cash Flow vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +639.4% is the highest of 8, against a peer median of -58.6%.
  • Investing cash flow amounts to 544.3% of revenue for SYRE, versus a peer median of 106.8%.
SYRE Competitors
Investing Cash Flow for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$492.54M USD+639.4%—544.3%
ANABAnaptysBio, Inc.LTM Mar 2026$248.17M USD+496.1%—106.8%
UPBUpstream Bio, Inc.LTM Mar 2026$162.3M USD+156.6%+944.6%4885.6%
ARDXArdelyx, Inc.LTM Mar 2026$21.81M USD+69.1%—5.1%
ABVXAbivax S.A.FY2025€13.18M EUR-183.6%+3.1%—
IFRXInflaRx N.V.LTM Mar 2026€8.18M EUR-119.0%-45.7%27899.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.69M USD-97.5%+56.5%20.2%
IMUXImmunic, Inc.LTM Mar 2026$116K USD-58.6%-74.5%—
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding SYRE) —-58.6%+3.1%106.8%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Depreciation & Amortization1.58M1.96M744K010M
Deferred Income Tax0(327K)000
Stock-Based Compensation8.04M7.11M25.68M44.83M37.61M
Change in Working Capital1.83M(5.5M)(5.21M)(4.53M)(5.93M)
Accounts Receivables(815K)440K375K00
Inventory0(440K)000
Accounts Payables1.07M(2.64M)218K(230K)7.65M
Other Working Capital1.58M(2.86M)(5.8M)(4.3M)(13.58M)
Other Non-Cash Items638K426K217.67M10.31M(55.73M)
Operating Cash Flow(53.72M)(80.14M)(99.91M)(157.41M)(169.25M)
Capital Expenditures(573K)(38K)000
Acquisitions (Net)003.04M00
Purchases of Investments(133.08M)(39.5M)(166.8M)(599.25M)(522.21M)
Sales of Investments111.03M96.55M39.9M245.97M371.74M
Other Investing Activities0015.48M07M
Investing Cash Flow(22.62M)57.01M(108.39M)(353.29M)(143.48M)
Debt Repayment(510K)(418K)(16K)00
Common Stock Issued042.87M169.11M236.38M314.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.9M222K(5.38M)5.67M(5.41M)
Financing Cash Flow1.39M42.68M361.08M410.91M309.03M
Effect of Forex Changes(15K)(106K)25K(3K)0
Net Change in Cash(74.96M)19.44M152.8M(99.79M)(3.7M)
Free Cash Flow(54.29M)(80.18M)(99.91M)(157.41M)(169.25M)

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.